Outcome of Board Meeting

YH/SE/50/2026-27 September 17, 2026 The Listing Department Dept. of Listing Operations National Stock Exchange of India Limited BSE Limited, Exchange Plaza, 5th Floor, Plot No. C/1 Phiroze Jeejeebhoy Towers, G Block, Bandra-Kurla Complex, Bandra (E) Dalal Street, Mumbai – 400 051, India Mumbai - 400001, India Symbol: YATHARTH Scrip Code: 543950 ISIN: INE0JO301016 ISIN: INE0JO301016 Sub.: Outcome of Board Meeting Re.: Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ‘Listing Regulations’) Dear Sir/Madam, In furtherance to our intimation dated September 14, 2026, we wish to inform you that the Board of Directors (“Board”) of Yatharth Hospital & Trauma Care Services Limited (“Company”) at their meeting held today i.e. September 17, 2026 has inter alia considered and approved the following: 1. The Increase in Authorised Share Capital and alteration of capital clause in the Memorandum of Association of the Company Subject to the approval of the shareholders of the Company, the Board has approved the increase in the authorised share capital of the Company from INR 115,00,00,000 (Indian Rupees One Hundred Fifteen Crores) divided into 11,50,00,000 (Eleven Crore Fifty Lakhs) equity shares of face value of INR 10 (Indian Rupees Ten) each, to INR 150,00,00,000 (Indian Rupees One Hundred Fifty Crores) divided into 15,00,00,000 (Fifteen Crores) equity shares of face value of INR 10 (Indian Rupees Ten) each. Consequently, Capital Clause (Clause V) of the Memorandum of Association of the Company shall be amended, subject to approval by shareholders of the Company and any other approvals under applicable laws. 2. Issuance and allotment of equity shares and warrants of the Company by way of preferential issue on a private placement basis Subject to the approval of the shareholders of the Company and receipt of approvals from applicable statutory authorities, as may be required, the Board has approved the issuance and allotment of the following securities by way of preferential issue on a private placement basis to Rasmalai Limited (the “Investor”), a company incorporated under the laws of Cyprus, with PAN AANCD0341F, and having its registered address at Kennedy 23, Globe House, Ground & 1st Floors, 1075, Nicosia, Cyprus, for a cash consideration aggregating upto INR 31,50,00,02,910.60 (Indian Rupees Three Thousand One Hundred and Fifty Crores and Two Thousand Nine Hundred Ten and Sixty Paisa Only) (the “Preferential Issue”): (i) up to 1,30,26,516 (One Crore Thirty Lakhs Twenty Six Thousand Five Hundred and Sixteen) fully paid-up equity shares of the Company of face value of INR 10 (Indian Rupees Ten) each (the “Subscription Shares”), at an issue price of INR 985.17 (Indian Rupees Nine Hundred and Eighty Five and Seventeen Paisa Only) per Subscription Share, for an aggregate Subscription Share consideration of INR 12,83,33,32,767.72 (Indian Rupees One Thousand Two Hundred Eighty Three Crore Thirty Three Lakhs Thirty Two Thousand Seven Hundred Sixty Seven and Seventy Two Paisa Only); and (ii) up to 1,89,47,664 (One Crore Eighty Nine Lakhs Forty Seven Thousand Six Hundred and Sixty Four) warrants of the Company (the “Subscription Warrants”), each carrying a right exercisable by the Investor to subscribe to 1 (one) fully paid-up equity share of face value of INR 10 (Indian Rupees Ten) each of the Company, at a per Subscription Warrant price of INR 985.17 (Indian Rupees Nine Hundred and Eighty Five and Seventeen Paisa Only), of which 25% (twenty five per cent), being INR 246.29 (Indian Rupees Two Hundred Forty Six and Twenty Nine Paisa Only) is payable upfront and the balance 75% (seventy five per cent), being INR 738.88 (Indian Rupees Seven Hundred Thirty Eight and Eighty Eight Paisa Only), is payable at the time of exercise of the Subscription Warrants, in accordance with the terms set out in Schedule IV of the Investment Agreement (defined below), (the Subscription Shares and the Subscription Warrants, together, the “Subscription Securities”). This minority investment is in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the “SEBI ICDR Regulations”), the provisions of the Companies Act, 2013 and the rules made thereunder (“Act”), and other applicable laws, and is subject to: (a) the approval of the shareholders of the Company; (b) receipt of applicable regulatory/governmental approvals; and (c) satisfaction of such other conditions precedent and other terms and conditions, as agreed between the parties in the Investment Agreement. The Subscription Securities to be issued and allotted by the Company and to be subscribed by the Investor shall represent a minority investment of 24.87% (Twenty-Four point Eight Seven percent) of the post-issue share capital of the Company on a fully diluted basis (factoring granted employee stock options issued by the Company to its employees) (“Proposed Transaction”). Upon completion of the Proposed Transaction, the Investor would be classified as a public shareholder of the Company. The Relevant Date, as per the relevant provisions of Chapter V of the SEBI ICDR Regulations, for determination of the floor price of the Subscription Securities shall be 15th September, 2026. The Floor Price of the equity shares determined in accordance with Chapter V of SEBI ICDR Regulations is INR 984.70 (Indian Rupees Nine Hundred Eighty-Four and Seventy Paisa) per Subscription Security. The Board also approved the issue price (“Subscription Price”) of the Subscription Securities as INR 985.17 (Indian Rupees Nine Hundred Eighty-Five and Seventeen Paisa) Per Subscription Security including premium of INR 975.17 (Indian Rupees Nine Hundred Seventy-Five and Seventeen Paisa) per Subscription Security. The details regarding issuance of Subscription Securities under Regulation 30 of the Listing Regulations read with SEBI Circular Ref. No. HO/49/14/14(7)2025-CFD-POD2/ I/3762/2026 dated January 30, 2026 (the “SEBI Circular”) are set out in Annexure I. In connection with the Preferential Issue, the Board also approved the execution of an investment agreement by the Company with the Investor, and Dr. Ajay Kumar Tyagi, Dr. Kapil Kumar, Dr. Neena Tyagi and Dr. Manju Tyagi (collectively, the “Promoters”) dated September 17, 2026 (the “Investment Agreement”). The details regarding the Investment Agreement, as required under Regulation 30 of the Listing Regulations read with clauses (5) and (5A) of Para A of Part A of Schedule III to the Listing Regulations and the SEBI Circular, are set out in Annexure II. 3. the Amended and Restated Articles of Association of the Company and grant of special rights to the Investor Subject to the approval of the shareholders of the Company and in compliance with the Listing Regulations and the Act, the Board has approved the adoption of the amended and restated articles of association of the Company (the “Restated Articles”) incorporating inter alia the rights and obligations of the Investor under the Investment Agreement. The rights proposed to be granted to the Investor qualify as special rights under Regulation 31B of the Listing Regulations and are also subject to approval of shareholders of the Company by a special resolution. The Restated Articles shall take effect from the Closing Date (as defined under the Investment Agreement). The brief details of the rights and obligations of the Investor being incorporated in the Restated Articles are set out in point 5 of Annexure II below. 4. the Amended and Restated Articles of Association of the Company and grant of rights to the Promoters Subject to approval of shareholders of the Company and in compliance with the Listing Regulations and the Act, the Board has approved the adoption of the amended and restated articles of association of the Company (the “Restated Articles”) incorp [Showing first 8,000 characters — download PDF for full document]